Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Fludrocortisone Acetate CAS 514-36-3 API Active Pharmaceutical Ingredient

Fludrocortisone Acetate CAS 514-36-3 API Active Pharmaceutical Ingredient

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 514-36-3

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:

Fludrocortisone Acetate CAS 514-36-3

,

Fludrocortisone Acetate Active Pharmaceutical Ingredient

,

CAS 514-36-3 API Ingredient

CAS NO::
514-36-3
Appearance::
Crystalline Solid
Molecular Formula::
C23H31FO6
Molecular Weight::
422.48700
EINECS NO::
208-180-4
MDL NO::
MFCD00056473
CAS NO::
514-36-3
Appearance::
Crystalline Solid
Molecular Formula::
C23H31FO6
Molecular Weight::
422.48700
EINECS NO::
208-180-4
MDL NO::
MFCD00056473
Fludrocortisone Acetate CAS 514-36-3 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Fludrocortisone acetate CAS NO: 514-36-3

 

 

 

Synonyms:

17-dihydroxy-20-dion(11-beta)-pregn-4-ene-21-(acetyloxy)-9-fluoro-11;

20-dione,9-fluoro-11-beta,17,21-trihydroxy-pregn-4-ene-21-acetate;

9-alpha-fluorohydrocortisone-21-acetate;

 

 

 

Chemical & Physical Properties:

Appearance: Crystalline solid

Assay :≥99.0%

Density: 1.3 g/cm3

Boiling Point: 575.1℃ at 760 mmHg

Melting Point: 233-234℃

Flash Point: 301.6℃

Refractive Index: 1.563

Storage Condition: -20℃ Freezer

Water Solubility: 54mg/L (25℃)

 

 

 

Safety Information:

RTECS: TU5050000

Risk Statements: R63

HS Code: 2937229000

Hazard Codes: Xn

Safety Statements: 22-26-36

WGK Germany : 3

 

 

 

ChEBI: An acetate ester resulting from the formal condensation of the primary hydroxy group of fludrocortisone with acetic acid. A synthetic corticosteroid, it has glucocorticoid actions about 10 times as potent as hydrocortisone, while its mineralocorticoid acti ns are over 100 times as potent. It is used in partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenal hyperplasia.

 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.